×
Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
https://acrabstracts.org/abstract/improving-the-efficiency-of-clinical-trial-recruitment-using-electronic-health-record-data-natural-language-processing-and-machine-learning/
Tianrun Cai, Fiona Cai, Kumar Dahal et. al.

Nov 13th, 2019 - Background/Purpose: Efficiently identifying eligible patients is an important component of a successful clinical trial.  Billing codes from electronic health record (EHR) data are commonly used to first screen for potential patients, followed by labor-intensive chart review to identify the eligible patients by trial criteria.  The objective of this study was to test whether a machine learning s...

Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative
https://acrabstracts.org/abstract/dietary-patterns-and-symptomatic-progression-of-knee-osteoarthritis-data-from-the-osteoarthritis-initiative/
Chang Xu, Nathalie Marchand, Jeffrey Driban et. al.

Nov 13th, 2019 - Background/Purpose: Osteoarthritis (OA) is a major source of disability worldwide yet dietary exposures that might be associated with its progression have not received significant research attention. We aimed to examine the prospective association of major dietary patterns derived by principal component analysis (PCA) with symptomatic progression of knee OA. Methods: From the Osteoarthritis Ini...

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Contro...
https://acrabstracts.org/abstract/dual-neutralization-of-il-17a-and-il-17f-with-bimekizumab-in-patients-with-active-psoriatic-arthritis-disease-activity-and-remission-in-a-48-week-phase-2b-randomized-double%e2%80%91blind-placebo-c/
Philip Mease, Laure Gossec, Laura Coates et. al.

Nov 13th, 2019 - Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of significant inflammatory disease activity’.1,2 Since many patients with PsA may not achieve clinical remission, treatment recommendations recognise minimal or low disease activity as an important alternative treatment t...

Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?
https://acrabstracts.org/abstract/does-the-degree-of-decline-in-walking-speed-predict-mortality-risk-beyond-the-present-level-of-walking-speed-in-knee-osteoarthritis/
Hiral Master, Tuhina Neogi, Lavalley Michael et. al.

Nov 13th, 2019 - Background/Purpose: Slow walking speed (WS) is a risk factor for mortality in well-functioning older adults and speeds slower than (< ) 1.22 meters per second (m/s) are a risk factor for poor health outcomes in knee osteoarthritis (OA). WS is known to decline with age, with some declining faster than other, though it is unclear if the rate of decline in WS is additionally relevant for mortality...

Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
https://acrabstracts.org/abstract/deriving-accurate-prednisone-dosing-from-electronic-health-records-analysis-of-a-natural-language-processing-tool-for-complex-prescription-instructions/
Francine Castillo, Adrienne Strait, Michael Evans et. al.

Nov 13th, 2019 - Background/Purpose: Prednisone is commonly used to treat rheumatic diseases, yet few comparative effectiveness studies on different dosing regimens are available. Electronic health records (EHR) and prescriptions are potential data sources for such research. However, a barrier to this work is organizing non-standardized prednisone “sigs”, or free-text instructions within a prescription, into a ...

DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
https://acrabstracts.org/abstract/dmard-free-remission-in-established-rheumatoid-arthritis-2-year-results-of-the-tara-trial/
Elise van Mulligen, Angelique Weel, Martijn Kuijper et. al.

Nov 13th, 2019 - Background/Purpose: In rheumatoid arthritis (RA) disease outcomes  have improved enormously in the last  decades. Due to early initiation of therapy, a treat-to-target approach and a growing arsenal of disease-modifying antirheumatic drugs (DMARDs) and biologicals, RA patients are in sustained remission more often. This raises the subsequent questions whether treatment should be continued, tape...

Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
https://acrabstracts.org/abstract/application-of-bayesian-statistics-to-support-approval-of-intravenous-belimumab-in-children-with-systemic-lupus-erythematosus-in-the-united-states/
Ginto Pottackal, James Travis, Rosemarie Neuner et. al.

Nov 13th, 2019 - Background/Purpose: In April 2019, FDA approved the first treatment, intravenous (IV) belimumab (BEL), specifically for children 5 to 17 years of age with active, seropositive SLE receiving standard care (SOC). The approval was supported by a single post-marketing required randomized, controlled trial (NCT01649765) that evaluated the efficacy, safety and pharmacokinetics (PK) of 10 mg/kg IV BEL...

Access to Care and Diagnostic Delays in Juvenile Dermatomyositis
https://acrabstracts.org/abstract/access-to-care-and-diagnostic-delays-in-juvenile-dermatomyositis/
Jessica Neely, Susan Kim, Hugh Sturrock 2 and Julia Shalen et. al.

Nov 13th, 2019 - Background/Purpose: Factors associated with diagnostic delay in Juvenile Dermatomyositis (JDM) are not known.  We hypothesized that limited access to pediatric rheumatologists can lead to delay in the diagnosis of JDM and worse outcomes. We investigated demographic factors, including access to care, associated with diagnostic delays and clinical outcomes of subjects with JDM in the Childhood Ar...

An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
https://acrabstracts.org/abstract/an-integrated-gut-microbiomic-and-plasma-metabolomic-analysis-in-patients-with-four-systemic-autoimmune-diseases/
Chiara Bellocchi, Álvaro Fernández-Ochoa, Gaia Montanelli et. al.

Nov 13th, 2019 - Background/Purpose: Gut microbiota may be relevant in the regulation of immune processes and in the development of systemic autoimmune diseases (SADs). A reduction of microbiota diversity and a selective decrease of commensal pro-regolatory bacteria have been observed in systemic lupus erythematosus (SLE), Sjogren syndrome (SJS) and primary anti-phosholipid syndrome (PAPS). None studies have be...

Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
https://acrabstracts.org/abstract/antimicrobial-use-is-high-in-patients-with-rheumatoid-arthritis-and-further-increases-with-first-line-tnfi-therapy-nationwide-results-from-iceland/
Aron H Bjornsson, Olafur Palsson, Mar Kristjansson et. al.

Nov 13th, 2019 - Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are needed. Our objective was to investigate the use of antimicrobials (antibiotics, antifungals and antivirals; excluding antimycobacterials) in patients with rheumatoid arthritis (R...

Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner
https://acrabstracts.org/abstract/hypoxia-resistant-pathogenic-b-cells-accumulate-in-the-ra-synovial-tissue-in-a-cxcr3-dependent-manner/
Achilleas Floudas, Candice Low, Monika Biniecka et. al.

Nov 13th, 2019 - Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown and complex aetiology with severe detrimental effects for the patient’s quality of life. While autoantibodies have been used extensively for the diagnosis of RA, no clear mechanism of action towards disease pathogenesis and progression has been identified. Importantly, both seropositive and ser...

High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis
https://acrabstracts.org/abstract/high-resolution-3d-fast-spin-echo-t1-black-blood-imaging-for-the-diagnosis-of-giant-cell-arteritis/
Christine rodriguez, Wagih Ben Hassen, Pierre Seners et. al.

Nov 13th, 2019 - Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis of large arteries affecting people older than 50 years. Temporal artery biopsy (TAB) is still considered as the gold standard for GCA diagnosis but it is invasive and its sensitivity ranges from 39 to 86%.Color Doppler Ultrasonography and PET-scanner have been proposed as alternative methods for GCA diagnosis b...

Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
https://acrabstracts.org/abstract/bromodomain-inhibitor-i-bet762-inhibits-production-of-pro-inflammatory-in-rheumatoid-arthritis-fibroblast-like-synoviocytes-and-differentiation-of-osteoclast/
Ra Ham Kim, Hyun Jung Yoo, Shin Eui Kang et. al.

Nov 12th, 2019 - Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder, characterized by joint inflammation and bone destruction. The fibroblast-like synoviocyte(FLS) contributes to the pathogenesis of RA through cellular proliferation and production of cytokines or chemokines. Recently, blockade of the bromodomain and extra-terminal domain (BET) family protein was reported to be a pote...

Cracks in Your Referral Process? Find Your Sustainable Solution Here
https://acrabstracts.org/abstract/cracks-in-your-referral-process-find-your-sustainable-solution-here/
Sheetal Vora, Amanda Moyer, Lynn Kalhagen et. al.

Nov 12th, 2019 - Background/Purpose: Early diagnosis for rheumatic conditions is crucial for children to achieve the best functional outcomes. Access to care is difficult due to the volume of referrals and paucity of pediatric rheumatologists. This compelling need to expediently triage dire and complex rheumatology referrals has been painfully demonstrated in our clinic. When this project was initiated there wa...

Beyond Genes—a Multi-omic Analysis of Monozygotic Twins Discordant for Rheumatoid Arthritis
https://acrabstracts.org/abstract/beyond-genes-a-multi-omic-analysis-of-monozygotic-twins-discordant-for-rheumatoid-arthritis/
Julia Manasson, Jeremy Sokolove, Lauren Lahey et. al.

Nov 12th, 2019 - Background/Purpose: Although a number of genetic factors, including susceptibility alleles, have been identified in rheumatoid arthritis (RA), the concordance rate in monozygotic (MZ) twins is only 15% (Silman AJ et al, Br J Rheumatol 1993). Given this relatively low rate, environmental factors (including smoking, the microbiome and others) likely play a significant role in disease pathogenesis...

Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive...
https://acrabstracts.org/abstract/baseline-characteristics-associated-with-sustained-sdai-remission-following-treatment-with-abatacept-in-combination-with-mtx-compared-with-abatacept-placebo-in-combination-with-mtx-in-acpa-positive-pa/
Paul Emery, Yoshiya Tanaka, Vivian Bykerk et. al.

Nov 12th, 2019 - Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) + MTX in adults with early RA.1 AVERT-2 was designed to demonstrate that ABA + MTX could achieve higher rates of SDAI remission versus ABA PBO + MTX and to test a clinically meaningful withdrawal strategy. Identifyin...

BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes
https://acrabstracts.org/abstract/batf2-contributes-to-interferon-dysregulation-in-sle-keratinocytes/
Jessica Turnier, Celine Berthier, Lam Tsoi et. al.

Nov 12th, 2019 - Background/Purpose: Skin inflammation can drive systemic disease in SLE, thus it is essential to understand the key regulators of the aberrant inflammatory response in lupus skin. We have previously identified BATF2 as a transcription factor that is highly overexpressed in lupus keratinocytes following type I IFN exposure. The objective of this study was to determine the role of BATF2 in regula...

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
https://acrabstracts.org/abstract/bone-mineral-density-in-psoriatic-arthritis-results-from-a-longitudinal-study/
Timothy Kwok, Justine (Yang) Ye, Daniel Pereira 2 and Dafna Gladman et. al.

Nov 12th, 2019 - Background/Purpose: Evidence thus far on the effect of psoriatic arthritis (PsA) on bone mineral density (BMD) has been inconsistent. There is also insufficient guidance surrounding BMD testing in PsA patients. The purpose of this study was to determine BMD in the PsA population, factors associated with having BMD testing performed, and the effect of PsA clinical activity on BMD. Methods: : Thi...

Bone Microstructure of Patients with Rheumatoid Arthritis: A HR-pQCT Study
https://acrabstracts.org/abstract/bone-microstructure-of-patients-with-rheumatoid-arthritis-a-hr-pqct-study/
Ikuko Tanaka, Takashi Kato, Hiroaki Mizuno et. al.

Nov 12th, 2019 - Background/Purpose: In rheumatoid arthritis (RA), it has been reported that osteoclast are activated by immune complexes, anti-CCP antibodies (ACPAs), and inflammatory cytokines. The purpose of this study was to investigate the relationship between bone microstructure and joint involvement by imaging the distal radius using HR-pQCT. Methods: Subjects were 127 female patients with RA, who were e...

Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
https://acrabstracts.org/abstract/body-mass-index-and-systemic-corticosteroid-use-as-indicators-of-disease-burden-and-their-influence-on-the-safety-profile-of-certolizumab-pegol-across-indications/
Vivian Bykerk, Andrew Blauvelt, Jeffrey Curtis et. al.

Nov 12th, 2019 - Background/Purpose: Certolizumab pegol (CZP) is an anti-TNF drug approved for rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD). Older age, comorbidities and corticosteroid (CS) use have been linked to increased risk of serious infectious events (SIEs) in CZP-treated patients (pts) with RA.1 However, the impact of ove...